Everything is ready in Brussels to host the European Forum for Industrial Biotechnology and Bioeconomy. Taking place on 9-11 October at SQUARE Brussels Meeting Centre, EFIB 2017 – organised by EuropaBio and Smithers Rapra – will take advantage of the opportunity to increase engagement between policy makers and a broad range of stakeholders connected with the existing biobased value chain, and reach a new network of end users from a range of industries.
With themes ranging from inspiring new business models, circular economy and the creation of markets, to addressing the issues of ensuring financing and funding is available for commercialisation, in addition to the availability of feedstocks, this year’s EFIB agenda will provide a comprehensive update on the status and outlook of biobased industries.
Some of the most important companies will provide their perspectives on the state of business in Europe, from developing new and novel partnerships along the value chain, to ensuring that capital investment is made available.
Joanna Dupont-Inglis, Industrial Biotechnology Director at EuropaBio comments that there are many reasons for optimism in 2017. The last twelve months have seen several key supports to biobased development put in place, including the launch of the French, Italian and Norwegian bioeconomy strategies. In parallel, Europe continues to see an increasingly high number of consumer brands, from automotive companies to sportswear, homecare, cosmetics and toy manufacturers, embracing the potential of new biobased materials.
Fast-moving consumer goods companies have also taken steps to embrace the circular economy and this hot topic will be addressed next October at EFIB.
While Industrial Biotechnology is currently estimated to be worth €28 billion in the EU, projections show that the EU market for IB products could develop to €40 billion by 2020 and up to €50 billion in 2050 with significant potential to become the dominant technology of Europe’s future chemicals industry. EFIB 2017 will bring the worlds of policy and business together to discuss how to boost investment, innovation and value chain development to capture the potential of white biotechnology in Europe.